Roche “Avenue” BP29647

Complete Study

A Phase III, Multi-Center, Multi-Dose, Double-Masked, Parallel Group to investigate the Safety and Tolerability of RO6867461 in patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration.

Duration: 36 weeks

This entry was posted in Uncategorized. Bookmark the permalink.